keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer, NSCLC, SCLC

keyword
https://www.readbyqxmd.com/read/29124886/cbx3-heterochromatin-protein-1-gamma-is-significantly-upregulated-in-patients-with-non-small-cell-lung-cancer
#1
Shih-Chieh Chang, Yi-Chun Lai, Yen-Chung Chen, Nai-Kuan Wang, Wei-Shu Wang, Jiun-I Lai
AIM: Lung cancer is typically categorized into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC comprises of the majority of lung cancer with a poor prognosis in advanced cases. Transcriptional profiling studies, including microarrays and RNA-sequencing studies, have significantly enriched our knowledge of gene expression patterns in NSCLC. A recent transcriptional profiling study identified high prevalence of CBX3/HP1-gamma upregulation in human NSCLC samples...
November 10, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29114469/update-on-large-cell-neuroendocrine-carcinoma
#2
REVIEW
Kenzo Hiroshima, Mari Mino-Kenudson
High-grade neuroendocrine carcinomas of the lung are classified into two categories: large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). While typical cases of LCNEC are morphologically distinct from SCLC, the differentiation between LCNEC and SCLC can be challenging in some cases. In fact, there are borderline high-grade neuroendocrine carcinomas that morphologically fall between LCNEC and SCLC. Growing evidence suggests that LCNEC is a histologically and biologically heterogeneous group of tumors...
October 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29110841/heterogeneous-resistance-mechanisms-in-an-egfr-exon-19-mutated-non-small-cell-lung-cancer-patient-treated-with-erlotinib-persistent-fgfr3-mutation-localized-transformation-to-egfr-mutated-sclc-and-acquired-t790m-egfr-mutation
#3
Eric Santoni-Rugiu, Morten Grauslund, Linea C Melchior, Junia C Costa, Jens B Sørensen, Edyta M Urbanska
Patients with epidermal growth factor receptor (EGFR) gene-mutated non-small cell lung cancer (NSCLC) obtain substantial clinical benefit from EGFR tyrosine-kinase inhibitors (TKIs), but will ultimately develop TKI-resistance resulting in median progression-free survival of 9-15 months during first-line TKI-therapy. However, type and timing of TKI-resistance cannot be predicted and several mechanisms may simultaneously/subsequently occur during TKI-treatment. In this respect, we present a 49 year-old Caucasian male ex-smoker with metastatic pulmonary adenocarcinoma (ADC) that concomitantly harbored an EGFR exon 19-mutation (p...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29066508/molecular-subtypes-of-pulmonary-large-cell-neuroendocrine-carcinoma-predict-chemotherapy-treatment-outcome
#4
Jules Derks, Noémie Leblay, Erik Thunnissen, Robert Jan van Suylen, Michael den Bakker, Harry Jm Groen, Egbert F Smit, Ronald Damhuis, Esther C van den Broek, Amelie Chabrier, Matthieu Foll, James D McKay, Lynnette Fernandez-Cuesta, Ernst-Jan M Speel, Anne-Marie C Dingemans
PURPOSE: Previous genomic studies have identified two mutually exclusive molecular subtypes of large-cell neuroendocrine carcinoma (LCNEC): the RB1 mutated (mostly co-mutated with TP53) and the RB1 wild-type groups. We assessed if these subtypes have a predictive value on chemotherapy outcome. EXPERIMENTAL DESIGN: Clinical data and tumor specimens were retrospectively obtained from the Netherlands Cancer Registry and Pathology Registry. Panel-consensus pathology revision confirmed the diagnosis of LCNEC in 148 of 232 cases...
October 24, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29061221/-advances-in-the-transformation-to-small-cell-lung-cancer-from-non-small-cell-lung-cancer-following-acquired-drug-resistance-to-egfr-tyrosine-kinase-inhibitors
#5
Wenqiu Zhang, Yongqi Li, Di Wu
The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of sensitive EGFR mutation in non-small cell lung cancer (NSCLC) has been proved significant curative effect. However, the acquisition of the drug resistance to EGFR-TKIs is almost inevitable, and common drug resistance mechanisms include T790M mutation, cMET amplification, etc. One of the rare resistance mechanisms of EGFR-TKIs is the transformation from NSCLC into small cell lung cancer (SCLC), which account for about 3%-15%...
October 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29050263/the-prognostic-value-of-osteopontin-in-limited-stage-small-cell-lung-cancer-patients-and-its-mechanism
#6
Fanglei Liu, Chunxue Bai, Zhongliang Guo
Osteopontin (OPN) is known to be overexpressed in numerous carcinomas. Although abundant OPN has been reported to be correlated with poor survival in non-small cell lung cancer (NSCLC) but their clinical and prognostic significance in SCLC remains unknown. In this study, RNA-sequencing was used to obtain gene expression data in SCLC tissue samples and OPN expression levels were then investigated using qPCR, immunohistochemical and Western blot. We found OPN was one of the most upregulated genes. Besides, the correlation of OPN with tumor clinicopathological characteristics was evaluated and we found OPN was associated with advanced tumor stages...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28976111/contribution-of-cell-blocks-obtained-through-endobronchial-ultrasound-guided-transbronchial-needle-aspiration-for-the-determination-of-lung-cancer-subtypes
#7
Nilgün Yılmaz Demirci, Asiye Uğraş Dikmen, Zarife Abdullayeva, Can Öztürk
INTRODUCTION: It is crucial to diagnose the subtype of lung cancer quickly and accurately for effective therapy. Conventional cytology staining sometimes provides limited information, and additional tissue is often required to diagnose lung cancer. Cell blocks (CB) recovered during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) increases the diagnostic accuracy of the procedure and the likelihood of additional valuable histochemical and immunohistochemical staining...
October 4, 2017: Clinical Respiratory Journal
https://www.readbyqxmd.com/read/28969072/development-and-validation-of-two-prognostic-nomograms-for-predicting-survival-in-patients-with-non-small-cell-and-small-cell-lung-cancer
#8
Hai-Fan Xiao, Bai-Hua Zhang, Xian-Zhen Liao, Shi-Peng Yan, Song-Lin Zhu, Feng Zhou, Yi-Kai Zhou
PURPOSE: This study aimed to construct two prognostic nomograms to predict survival in patients with non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) using a novel set of clinical parameters. PATIENTS AND METHODS: Two nomograms were developed, using a retrospective analysis of 5384 NSCLC and 647 SCLC patients seen during a 10-year period at Xiang Ya Affiliated Cancer Hospital (Changsha, China). The patients were randomly divided into training and validation cohorts...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28967066/clinical-implications-for-pro-grp-in-small-cell-lung-cancer-a-single-center-experience
#9
Stefano Cavalieri, Daniele Morelli, Antonia Martinetti, Giulia Galli, Federico Nichetti, Filippo de Braud, Marco Platania
BACKGROUND: Recently, pro-gastrin-releasing peptide (pro-GRP) became available as an alternative sensitive, specific and reliable tumor marker for patients with small cell lung cancer (SCLC), both in limited (LD) and diffuse disease (DD). METHODS: We retrospectively analyzed pro-GRP, neuron-specific enolase (NSE) and CEA in patients with SCLC and non-small cell lung cancer (NSCLC). Serum pro-GRP level was measured with electrochemiluminescence at our laboratory (cutoff 77...
September 25, 2017: International Journal of Biological Markers
https://www.readbyqxmd.com/read/28928901/systematic-correlation-analyses-of-circulating-tumor-cells-with-clinical-variables-and-tumor-markers-in-lung-cancer-patients
#10
Xu Wang, Kewei Ma, Zhiguang Yang, Jiuwei Cui, Hua He, Andrew R Hoffman, Ji-Fan Hu, Wei Li
Measurement of circulating tumor cells (CTC) offers promise as a clinical biomarker to monitor disease status, therapeutic response, and progression in cancer patients. However, its clinical value in lung cancer patients has not been fully explored. We systematically evaluate the association of CTCs with clinical variables and tumor markers in a cohort of lung cancer patients. Using the CELLSEARCH System, CTCs were detected in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients prior to therapy...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28910952/-establishment-of-cut-off-value-of-serum-pro-gastrin-releasing-peptide-for-diagnosis-of-small-cell-lung-cancer-and-evaluation-on-the-clinical-diagnosis-efficiency
#11
D Shen, B B Han, F Chen, B J Wei, C J Cui, G J Wang, W Cui
Objective: To determine critical reference value (cut-off value) of serum pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase(NSE) in the diagnosis of small cell lung cancer(SCLC). To evaluate the clinical significance of serum levels of ProGRP and NSE in diagnosis and differential diagnosis in SCLC. Methods: Three hundred and fifty-two SCLC patients, 163 non small cell lung cancer(NSCLC)patients , 193 benign pulmonary disease patients and 140 healthy people visiting in National Cancer Hospital were analyzed retrospectively from January 2014 to July 2017...
September 12, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/28904884/circulating-tumor-cells-and-cdx-models-as-a-tool-for-preclinical-drug-development
#12
REVIEW
Alice Lallo, Maximilian W Schenk, Kristopher K Frese, Fiona Blackhall, Caroline Dive
Lung cancers are the main cause of cancer-related deaths worldwide. Efforts placed to improve the survival of lung cancer patients and untangle the complexity of this disease, have resulted in the generation of hundreds of lung cancer cell lines and several genetically engineered mouse models (GEMMs). Although these research tools have extended our knowledge of lung cancer, improvement in the clinical care of lung cancer patients have been limited overall, with measured optimism regarding initial responses to targeted therapies in stratified subgroups of patients...
August 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28900491/the-clinical-effect-of-metformin-on-the-survival-of-lung-cancer-patients-with-diabetes-a-comprehensive-systematic-review-and-meta-analysis-of-retrospective-studies
#13
Xun Cao, Zhe-Sheng Wen, Xu-Dong Wang, Yong Li, Kui-Yuan Liu, Xin Wang
Preclinical investigations have revealed an anti-cancer effect of metformin. Several studies of metformin treatment have demonstrated the improved clinical outcomes of lung cancer patients with diabetes; however, the results have been inconsistent among studies. Our systematic review and meta-analysis aimed to summarize the up-to-date effects of metformin on diabetic lung cancer patients. A systematic search was performed for studies published. Then, these studies were evaluated for inclusion, and relevant data was extracted...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28898877/identification-of-small-and-non-small-cell-lung-cancer-markers-in-peripheral-blood-using-cytokinesis-blocked-micronucleus-and-spectral-karyotyping-assays
#14
Randa A El-Zein, Shereen Abdel-Rahman, Kyle J Santee, Robert Yu, Sanjay Shete
Small cell lung cancer (SCLC) is a highly aggressive form of lung cancer. There is an urgent need to develop tools to identify individuals at high risk of developing SCLC. We have previously reported that the cytokinesis-blocked micronucleus (CBMN) assay is a strong predictor of non-small cell lung cancer (NSCLC). Here, we investigate the sensitivity of the CBMN endpoints as predictors of SCLC risk. We conducted the CBMN assay on SCLC patients (n = 216), NSCLC patients (n = 173), and healthy controls (n = 204)...
2017: Cytogenetic and Genome Research
https://www.readbyqxmd.com/read/28895411/knockdown-of-human-serine-threonine-kinase-33-suppresses-human-small-cell-lung-carcinoma-by-blocking-rps6-bad-signaling-transduction
#15
E L Sun, C X Liu, Z X Ma, X Y Mou, X A Mu, Y H Ni, X L Li, D Zhang, Y R Ju
Small cell lung cancer (SCLC) is characterized by rapid growth rate and a tendency to metastasize to distinct sites of patients' bodies. The human serine/threonine kinase 33 (STK33) gene has shown its potency as a therapeutic target for prevention of lung carcinomas including non-small cell lung cancer (NSCLC), but its function in the oncogenesis and development of SCLC remains unrevealed. In the current study, it was hypothesized that STK33 played a key role in the proliferation, survival, and invasion of SCLC cells...
September 12, 2017: Neoplasma
https://www.readbyqxmd.com/read/28888381/long-term-observation-of-ct-guided-radiofrequency-ablation-of-lung-neoplasm-in-476-consecutive-patients-by-a-thoracic-surgical-service-a-single-institutional-experience
#16
Bing-Yang Huang, Jun-Jun Zhou, Zhi-Qi Yu, Xiao-Yong Song, Yi Lin, Xin-Min Li, Lu Li
RATIONALE AND OBJECTIVES: The aim of the study was to evaluate the overall survival (OS) rate, progression survival rate, and local control rate over 10 years of medically inoperable patients with lung cancer undergoing computed tomography (CT)-guided radiofrequency ablation (RFA). MATERIALS AND METHODS: Between September 2004 to March 2016, 668 neoplasms were treated in 476 medically inoperable patients (294 men, 60 women; median age 74 years; range 29-84) who underwent CT-guided RFA...
September 6, 2017: Academic Radiology
https://www.readbyqxmd.com/read/28878044/progress-and-prospects-of-early-detection-in-lung-cancer
#17
REVIEW
Sean Blandin Knight, Phil A Crosbie, Haval Balata, Jakub Chudziak, Tracy Hussell, Caroline Dive
Lung cancer is the leading cause of cancer-related death in the world. It is broadly divided into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer (NSCLC, approx. 85% cases). The main histological subtypes of NSCLC are adenocarcinoma and squamous cell carcinoma, with the presence of specific DNA mutations allowing further molecular stratification. If identified at an early stage, surgical resection of NSCLC offers a favourable prognosis, with published case series reporting 5-year survival rates of up to 70% for small, localized tumours (stage I)...
September 2017: Open Biology
https://www.readbyqxmd.com/read/28860576/pd-l1-expression-in-lung-cancer-and-its-correlation-with-driver-mutations-a-meta-analysis
#18
Minghui Zhang, Guoliang Li, Yanbo Wang, Yan Wang, Shu Zhao, Pu Haihong, Hongli Zhao, Yan Wang
Although many studies have addressed the prognostic value of programmed cell death-ligand 1 (PD-L1) expression in lung cancer, the results remain controversial. A systematic search of the PubMed, EMBASE, and Cochrane Library databases was performed to identify the correlation between PD-L1 expression and driver mutations and overall survival (OS). This meta-analysis enrolled a total of 11,444 patients for 47 studies, and the pooled results showed that increased PD-L1 expression was associated with poor prognosis (HR = 1...
August 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28856088/syndrome-of-inappropriate-secretion-of-anti-diuretic-hormone-siadh-as-an-initial-presenting-sign-of-non-small-cell-lung-cancer-case-report-and-literature-review
#19
Praneet Iyer, Mohammad Ibrahim, Waqas Siddiqui, Ahmed Dirweesh
Association of SIADH with malignancy was first reported in 1957, when it was described in two patients with bronchogenic carcinoma. While the association with small cell lung cancer (SCLC) is well known, that with non small cell lung cancer (NSCLC) has been rarely reported. We report a case of 70 year old male who was found to have hyponatremia secondary to SIADH. Radiological tests revealed right hilar lung mass with mediastinal adenopathy. Bronchoscopic biopsy revealed non-small cell lung cancer of type squamous cell...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/28838401/lack-of-response-to-nivolumab-in-a-patient-with-egfr-mutant-non-small-cell-lung-cancer-adenocarcinoma-sub-type-transformed-to-small-cell-lung-cancer
#20
Nadza Tokaca, Andrew Wotherspoon, Andrew G Nicholson, Nicos Fotiadis, Lisa Thompson, Sanjay Popat
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
keyword
keyword
13192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"